| HOME >> BIOLOGY >> TECHNOLOGY |
WOODCLIFF LAKE, N.J., Aug. 23 /PRNewswire/ -- Eisai Corporation of North America and its partner Helsinn Healthcare SA today announced that the U.S. Food and Drug Administration (FDA) has approved a new oral formulation of ALOXI(R) (palonosetron hydrochloride) for the prevention of chemotherapy-induced nausea and vomiting (CINV). ALOXI Capsules 0.5 mg for oral administration is indicated for the prevention of acute nausea and vomiting following initial and repeat courses of moderately emetogenic chemotherapy. A single 0.5 mg ALOXI Capsule is administered approximately one hour prior to the start of chemotherapy.
ALOXI (palonosetron hydrochloride) injection 0.25 mg, a 5-hydroxytryptamine-3 (5-HT3) receptor antagonist, has been available in the United States for intravenous administration since 2003 for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy, and for the prevention of acute nausea and vomiting associated with initial and repeat courses of highly emetogenic chemotherapy. A single 0.25 mg intravenous dose of ALOXI is administered approximately 30 minutes before the start of chemotherapy.
About Chemotherapy-Induced Nausea and Vomiting (CINV)
Research has shown that patients with cancer consider CINV among the most dreaded side effects following therapy. Despite prophylactic antiemetics, on the day of chemotherapy, about 30-45 percent of patients experience nausea or vomiting or require rescue therapy following administration of moderately emetogenic chemotherapy. Failure to control acute nausea and vomiting on the first day of chemotherapy will increase the risk of nausea and vomiting on subsequent days and in subsequent cycles of chemotherapy.
About ALOXI Capsules for Oral Administration
ALOXI (palonosetron HCl) Capsules 0.5 mg for oral administration is
indicated for the prevention of acute nausea and vomiting associated with
initi
'/>"/>
| SOURCE Eisai Corporation of North America Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. USDA Approves Syngenta and John Deere for Broadened Biotechnology Endorsement for Corn Crop Insurance
2. Signalife Board Approves Merger
3. FDA Approves EOVIST(R) to Detect and Characterize Focal Liver Lesions
4. FDA Approves Abbotts XIENCE(TM) V Drug Eluting Stent
5. FDA Approves ACIPHEX(R) (rabeprazole sodium) 20 mg for Short-Term Treatment of GERD in Adolescents
6. FDA Approves CONCERTA(R) (methylphenidate HCI) Extended-release Tablets for Treatment of ADHD (Attention Deficit Hyperactivity Disorder) in Adults
7. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
8. Big Win for Biodiesel: ASTM Approves New Biodiesel Blend Specifications
9. FDA Approves GlaxoSmithKlines AVODART(R) in Combination with Tamsulosin for the Treatment of Symptomatic Enlarged Prostate
10. Arpida Annual General Meeting of Shareholders Approves All Board Proposals
11. FDA Approves MIXJECT(TM), a Convenient, Easy-to-Use Drug Delivery System For Watson Pharmaceuticals TRELSTAR(R) DEPOT and TRELSTAR(R) LA
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |